Drug Profile
Insulin biosimilar - Curaxys
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 24 Jun 2015 Discontinued for Type-1 diabetes mellitus in Spain (Parenteral)
- 24 Jun 2015 Discontinued for Type-2 diabetes mellitus in Spain (Parenteral)